

NUPATHE INC.  
Form 8-K  
October 19, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 19, 2010**

**NuPathe Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation)

**001-34836**

(Commission File Number)

**20-2218246**

(IRS Employer Identification No.)

**227 Washington Street**

**Suite 200**

**Conshohocken, Pennsylvania**

(Address of Principal Executive Offices)

**19428**

(Zip Code)

Registrant's telephone number, including area code: **(484) 567-0130**

**Not Applicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On October 19, 2010, NuPathe Inc.® issued a press release announcing certain top-line results from a 12 month open-label, safety trial for Zelrix™, as well as the development of an *in vitro* analytical testing method for Zelrix. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following press release is furnished as Exhibit 99.1 to this Form 8-K pursuant to Item 7.01 and shall not be deemed to be “filed”:

99.1 Press release, dated October 19, 2010, issued by NuPathe Inc.

- 2 -

2

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NUPATHE INC.**

By: /s/ Keith A. Goldan

Keith A. Goldan

Chief Financial Officer

Dated: October 19, 2010

- 3 -

3

---

**EXHIBIT INDEX**

Exhibit No.	Description of Exhibit
99.1	Press release, dated October 19, 2010, issued by NuPathe Inc.